Evidence map›Paper›PMID 33355495›Full record

ArticlePharmaceutical biology2020

Pharmacokinetic interaction study between ligustrazine and valsartan in rats and its potential mechanism.

Yang Liu, Jiaqi Zhang, Di Wu, Liran Cui

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yang LiuDepartment of Pharmacy, The First Affiliated Hospital of Qiqihar Medical University, Fularji District, Qiqihar, China.
Jiaqi ZhangDepartment of Pharmacy, The First Affiliated Hospital of Qiqihar Medical University, Fularji District, Qiqihar, China.
Di WuCentral Laboratory, The First Affiliated Hospital of Qiqihar Medical University, Fularji District, Qiqihar, China.
Liran CuiCentral Laboratory, The First Affiliated Hospital of Qiqihar Medical University, Fularji District, Qiqihar, China.
Qiqihar Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextLigustrazine and valsartan are commonly used drugs in the treatment of cardiac and cardiovascular disease.

objectiveThe interaction between ligustrazine and valsartan was studied to investigate the effect of ligustrazine on the pharmacokinetics of valsartan. MATERIALS AND

methodsThe pharmacokinetics of valsartan (10 mg/kg) was investigated in Sprague-Dawley rats divided into three groups (with the pretreatment of 4 or 10 mg/kg/day ligustrazine for 10 days and without the pretreatment of ligustrazine as control) of six rats each. The

resultsLigustrazine changed the pharmacokinetic profile of valsartan. In the presence of 4 mg/kg ligustrazine, the AUC DISCUSSION AND

conclusionsLigustrazine promoted the metabolism of valsartan via activating CYP3A4. The co-administration of ligustrazine and valsartan should be taken into account.

Indexed as

AnimalsCytochrome P-450 CYP3A InducersDrug InteractionsMalePyrazinesRatsRats, Sprague-DawleyValsartanCytochrome P-450 CYP3A InducersPyrazinestetramethylpyrazineValsartanCYP3A4drug–drug interactionMetabolic stabilitymetabolism

Identifiers

PMID33355495
PMCPMC7759250
OpenAlexW3114039896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.